Spruce Biosciences downgraded by H.C. Wainwright
$SPRB
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright downgraded Spruce Biosciences from Buy to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/23/2025 | $283.00 | Outperform | Oppenheimer |
| 12/3/2025 | $160.00 | Market Perform → Outperform | Leerink Partners |
| 10/28/2025 | $254.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
| 12/11/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 12/11/2024 | Outperform → Perform | Oppenheimer | |
| 3/14/2024 | Buy → Neutral | Guggenheim | |
| 3/14/2024 | $9.00 → $2.00 | Outperform → Market Perform | Leerink Partners |
| 3/14/2024 | $9.00 → $2.00 | Outperform → Sector Perform | RBC Capital Mkts |
Oppenheimer initiated coverage of Spruce Biosciences with a rating of Outperform and set a new price target of $283.00
Leerink Partners upgraded Spruce Biosciences from Market Perform to Outperform and set a new price target of $160.00
Citizens JMP upgraded Spruce Biosciences from Mkt Perform to Mkt Outperform and set a new price target of $254.00
Treatment with Weekly TA-ERT Demonstrated Rapid and Durable Normalization of Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE), a Surrogate Endpoint Reasonably Likely to Predict Clinical Benefit TA-ERT Treatment Stabilized and Preserved Cognitive and Non-Cognitive Outcomes, such as Communication and Motor Skills for Over Six-Year Period Relative to Natural History Patients Safety Profile Consistent with Intracerebroventricular Administration with ~6,000 Doses Administered Over Six-Year Period Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with signific
Daven Mody, Pharm.D., Appointed as Senior Vice President, Regulatory and Quality Bruno Gagnon, B.Pharm., M.Sc., Appointed as Senior Vice President, Clinical Development Operations Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointments of Daven Mody, Pharm.D., as Senior Vice President of Regulatory and Quality and Bruno Gagnon, B.Pharm., M.Sc., as Senior Vice President, Clinical Development Operations. "We are delighted to welcome both Daven and Bruno to the executive leadership team during a transformative ti
Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfillipo syndrome type B (MPS IIIB) will be presented at the 22nd Annual WORLDSymposium™ taking place February 2-6, 2026 in San Diego. A second presentation will detail divergent outcomes in two male siblings, one of whom was treated with TA-ERT in a clinical trial while the other received care without treatment. WORLDSymposium 2026 Presentation Detai
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)
Keli Walbert brings decades of commercial leadership experience and a proven track record of successful product launches in rare disease Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Keli Walbert to the Company's Board of Directors. "Keli joins the Board of Directors at a pivotal time as we prepare for a Biologics License Application for TA-ERT for the treatment of Sanfilippo Syndrome Type B (MPS IIIB)," said Michael Grey, Executive Chairman of Spruce Biosciences. "Her experience in successfully launch
Spruce Reports Interim Data from Phase 2 POWER Proof-of-Concept Study in Polycystic Ovary Syndrome (PCOS) CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Surpasses 75% Enrollment in CAHmelia-203 and Approaches 75% Enrollment in CAHmelia-204 Screening Underway for Cohort 3 in CAHptain Study for Pediatric Classic CAH Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates. "Our goal with the POWER study is to ass
Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Percival Barretto-Ko to the company's Board of Directors. Concurrently, Dina Chaya, Ph.D., has stepped down from the Board of Directors. "On behalf of Spruce, I am pleased to welcome Percival Barretto-Ko to our Board of Directors," said Mike Grey, Executive Chairman of Spruce Biosciences. "Percival is an accomplished and
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (NASDAQ:SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce[1].
Biologics License Application (BLA) Submission to U.S. FDA for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Anticipated in 1H 2026 Spruce to Host Conference Call Today at 8:30 a.m. ET Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the company's new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). "This is truly a transformative moment for Spruce as we focus our expertise in rare disease on a potential near-te
CAHmelia-203 Study of Tildacerfont in Adult Classic Congenital Adrenal Hyperplasia (CAH) with Severe Hyperandrogenemia Did Not Meet Primary Efficacy Endpoint Positive Data from CAHptain-205 Study of Tildacerfont in Pediatric Classic CAH Supports Further Dose-Ranging Across Additional Dosing Cohorts Topline Results from CAHmelia-204 Study of Tildacerfont in Adult Classic CAH Evaluating Glucocorticoid (GC) Reduction Anticipated in Third Quarter of 2024 Resource Prioritization and Cost Reductions Extend Cash Runway Through End of 2025 Conference Call Today at 4:30 p.m. ET Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commerci
SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)
SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)